In Vivo Model Development for Constipation

Ace Therapeutics offers a comprehensive suite of in vivo animal model development services for Constipation research, supporting drug discovery and preclinical evaluation of novel therapeutics. Leveraging a wide range of validated animal models across multiple species and strains, our solutions are designed to provide robust, translational data to accelerate your constipation treatment development programs.

Constipation is a prevalent gastrointestinal disorder with significant impacts on patient quality of life. Accurate animal models are essential for understanding disease mechanisms and evaluating new therapeutic interventions. At Ace Therapeutics, we employ a diverse portfolio of species, including mice (Balb/c, C57BL/6, CD-1, Kunming, ddY), rats (Sprague Dawley, Wistar, CD), guinea pigs, and beagle dogs. These models are induced using clinically relevant agents or interventions such as loperamide, morphine, diphenoxylate, clonidine, sucralfate, dietary manipulation, and genetic modification. This diversity enables us to mimic various pathophysiological aspects of human constipation, ensuring high translational relevance and predictive validity for preclinical research.

Chemically-Induced Models

Chemically-induced constipation models are established by administering pharmacological agents (e.g., loperamide, morphine, diphenoxylate, clonidine, sucralfate, codeine, methadone, fentanyl) that reduce intestinal motility or alter fluid absorption. These models are implemented in a variety of species and strains, including mice, rats, guinea pigs, and dogs. Key advantages include rapid and reproducible onset, dose-dependent severity, and strong relevance to drug-induced constipation in humans. These models are ideal for screening prokinetic agents, evaluating opioid-induced constipation therapies, and mechanistic studies of gut motility.

Dietary Models

Dietary models of constipation are created through nutritional interventions, such as the administration of a low-fiber diet, which leads to decreased fecal output and impaired gut motility. These models, commonly implemented in rats, closely reflect the dietary causes of constipation observed in clinical populations. Advantages include non-invasive induction, chronicity, and the ability to assess long-term dietary and therapeutic interventions. Primary applications include the study of functional constipation, dietary supplement efficacy, and gut microbiome interactions.

Genetic and Surgical Models

Genetic and surgical models involve the use of genetically modified animals (e.g., Oprm1 knockout mice) or surgical interventions (e.g., vagotomy) to induce constipation. These models allow researchers to dissect the roles of specific genes or neural pathways in gastrointestinal motility. Advantages include mechanistic insight into disease etiology, the ability to model refractory or idiopathic constipation, and suitability for studying gene-targeted therapies. These models are particularly valuable for elucidating molecular targets and validating precision medicine approaches.

Ace Therapeutics delivers end-to-end in vivo constipation model services, including model selection and customization, protocol development, compound administration, and comprehensive data analysis. We offer a full suite of efficacy endpoints, such as stool frequency and weight, intestinal transit time, fecal water content, gastrointestinal motility assays, histopathological analysis, and biomarker quantification. Our analytical capabilities encompass advanced imaging, molecular biology, and statistical analysis to ensure robust and reproducible results. Quality control is maintained through standardized protocols, rigorous animal welfare practices, and continuous performance monitoring to guarantee scientific validity and regulatory compliance.

By partnering with Ace Therapeutics, you gain access to a highly experienced team, state-of-the-art facilities, and a proven track record in preclinical gastrointestinal research. Our flexible, client-focused approach ensures your unique project needs are met with precision and efficiency. Let us help you accelerate your constipation drug development pipeline with scientifically validated, translationally relevant animal model data. Contact us today to discuss your project requirements and discover how Ace Therapeutics can support your research goals.